Here’s Why FibroGen Stock Is Plunging Today
What happened
FibroGen(NASDAQ:FGEN) stock imploded Friday after an FDA advisory panel voted Thursday against approving the company’s lead drug candidate, roxadustat. Shares of the biotech were down by around 46% as of 1:20 p.m. EDT.
So what
The FDA convened…
